諾輝健康-B(06606.HK)擬不超3000萬美元投資於基金 專注於癌症及重大疾病領域疾病篩查及早期檢測分子診斷技術領域
格隆匯6月11日丨諾輝健康-B(06606.HK)公吿,於2021年6月11日,董事會舉行會議,於會上審議及批准有關公司(透過特殊目的公司)作為有限合夥人以總額不超過3000萬美元建議投資於基金(將於首次公開發售前自現有現金撥付)的決議案,據此,董事會授權執行董事及本公司管理團隊:
(i)採取任何對就建議交易註冊成立特殊目的公司屬必要的行動;(ii)磋商及落實特殊目的公司就建議交易將訂立的相關認購協議、有限合夥協議及任何其他文件或協議(倘適用)的條款;及(iii)採取對進行建議交易屬必要的任何其他行動。
基金將為有限合夥企業,主要專注於投資用於癌症及其他重大疾病類別領域疾病篩查及早期檢測的分子診斷技術領域。截至本公吿日期及據董事所深知,基金尚未成立且基金尚未識別到潛在投資目標。基金的普通合夥人將為NHHVenturesGP,Ltd(為投資控股公司及獨立第三方),其最終實益擁有人為Dr.EthanHu(為獨立第三方)。截至公吿日期及據董事所深知,基金的其他有限合夥人的身份尚未確認。
此外,楊靜文已辭任而莫明慧已獲委任公司以下職位,自2021年6月11日起生效。(i)聯席公司祕書;(ii)根據上市規則第3.05條的授權代表;及(iii)根據上市規則第19.05(2)條規定代表公司在香港接收法律程序文件及通知的代理人。
高煜將繼續擔任另一名聯席公司祕書。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.